Therapy assessment in prostate cancer using imaging surrogate markers for the PI3K-AKT-mTORC- and AR-pathway (B11*)

复发性前列腺癌通常被不同的雄激素受体(AR)调节剂治疗，其高表达的前列腺特异性膜抗原(PSMA)构成了理想的影像和放射配基治疗靶点。本项目的主要目的是研究PSMA配体PET作为PI3K-AKT-mTORC和AR-受体轴活性的潜在替代标志物，并开发和评价区分雄激素依赖型(AD)和CRPC(κ-阿片受体激动剂，前列腺酸性磷酸酶)的探针。将评估在AR靶向治疗下PSMA的潜在预靶向性，以及放射增敏剂在PSMA放射配基治疗中的附加作用。

Recurrent prostate cancer commonly being treated with different androgen-receptor(AR)-modulating agents is highly expressing the prostate-specific-membrane-antigen (PSMA) constituting an ideal target for imaging and radioligand therapy. The primary aim of this project is to investigate PSMA-ligand PET as potential surrogate marker for activity of the PI3K-AKT-mTORC and AR-receptor axis and to develop and evaluate probes for differentiation of androgen-dependent (AD) and CRPC (κ-opioid receptor agonists, Prostatic Acid Phosphatase). Potential pre-targeting of PSMA under AR-targeted therapy as well as additive effect of radiosensitizer on PSMA radioligand therapy will be assessed.